Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?

Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are widespread noncommunicable diseases in the global population. Since hypertension and NAFLD are diseases associated with metabolic syndrome, they are often comorbid. In fact, many contemporary published studies confirm the association of these diseases with each other, regardless of whether other metabolic factors, such as obesity, dyslipidemia, and type 2 diabetes mellites, are present. This narrative review considers the features of the association between NAFLD and AH, as well as possible pathophysiological mechanisms.

[1]  J. Linseisen,et al.  Association between fatty liver index and blood coagulation markers: a population-based study , 2023, Lipids in Health and Disease.

[2]  A. Vallée Associations between smoking and alcohol consumption with blood pressure in a middle-aged population , 2023, Tobacco induced diseases.

[3]  R. Francés,et al.  The shaping of gut immunity in cirrhosis , 2023, Frontiers in Immunology.

[4]  Annet Kirabo,et al.  Gut microbiota dependant trimethylamine N-oxide and hypertension , 2023, Frontiers in Physiology.

[5]  F. Marques,et al.  A major mechanism for immunomodulation: Dietary fibres and acid metabolites. , 2023, Seminars in immunology.

[6]  D. Monleón,et al.  Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease , 2023, World journal of clinical cases.

[7]  Young Mee Kim,et al.  Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics , 2023, Applied Biological Chemistry.

[8]  Haofei Hu,et al.  Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study , 2023, Diabetes, metabolic syndrome and obesity : targets and therapy.

[9]  M. Trauner,et al.  The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation , 2023, Scientific Reports.

[10]  R. Kreutz,et al.  Sex and gender in hypertension guidelines , 2023, Journal of Human Hypertension.

[11]  Beata Franczyk,et al.  Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure , 2023, International journal of molecular sciences.

[12]  L. Cugusi,et al.  Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors , 2023, International journal of molecular sciences.

[13]  I. Mogilnicka,et al.  Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats , 2022, Journal of Translational Medicine.

[14]  C. Tsioufis,et al.  Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort , 2022, Hypertension Research.

[15]  H. Lee,et al.  Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years , 2022, Cardiovascular Diabetology.

[16]  Jibo He,et al.  The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease , 2022, Nutrients.

[17]  J. Cai,et al.  Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community–Based Cohort Study , 2022, Frontiers in Endocrinology.

[18]  E. J. Belin de Chantemèle,et al.  Salt Sensitivity of Blood Pressure in Women , 2022, Hypertension.

[19]  A. Sanyal,et al.  Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality , 2022, Frontiers in Cardiovascular Medicine.

[20]  D. Roccarina,et al.  Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. , 2022, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[21]  M. Mahtab,et al.  Gender Differences in Nonalcoholic Fatty Liver Disease , 2022, Euroasian journal of hepato-gastroenterology.

[22]  Yang Zou,et al.  Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population , 2022, BMC Gastroenterology.

[23]  Miyang Luo,et al.  Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease , 2022, Frontiers in Immunology.

[24]  Qingzhi Huang,et al.  Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study , 2022, Journal of Human Hypertension.

[25]  A. Leite-Moreira,et al.  Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review , 2022, Metabolites.

[26]  G. Nam,et al.  Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease , 2022, Journal of obesity & metabolic syndrome.

[27]  Gerui Li,et al.  Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies , 2022, International journal of endocrinology.

[28]  C. Delles,et al.  Sex Differences in the Prevalence, Outcomes and Management of Hypertension , 2022, Current Hypertension Reports.

[29]  Longjian Liu,et al.  The association between bilirubin and hypertension among a Chinese ageing cohort: a prospective follow-up study , 2022, Journal of translational medicine.

[30]  Haiyang Tang,et al.  Gut Microbial Metabolite Trimethylamine N-Oxide Aggravates Pulmonary Hypertension. , 2022, American journal of respiratory cell and molecular biology.

[31]  Ju-Mi Lee,et al.  The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients , 2022, International journal of environmental research and public health.

[32]  M. Thursz,et al.  The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.

[33]  A. Aloisi,et al.  Estrogens and phytoestrogens in body functions , 2021, Neuroscience & Biobehavioral Reviews.

[34]  Xi Yang,et al.  Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy , 2021, Frontiers in Cardiovascular Medicine.

[35]  L. Poretsky,et al.  Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) , 2021, Metabolism open.

[36]  G. Mancia,et al.  Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis , 2021, European journal of gastroenterology & hepatology.

[37]  Xiaoming Tu,et al.  The Role of Short-Chain Fatty Acids of Gut Microbiota Origin in Hypertension , 2021, Frontiers in Microbiology.

[38]  S. Ishihara,et al.  Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome , 2021, International journal of molecular sciences.

[39]  S. Della Torre Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology , 2021, Cells.

[40]  A. Patzak,et al.  Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II–induced hypertension , 2021, Redox biology.

[41]  F. Galletti,et al.  Serum leptin is associated with increased pulse pressure and the development of arterial stiffening in adult men: results of an eight-year follow-up study , 2021, Hypertension Research.

[42]  F. Soriguer,et al.  Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study , 2021, Scientific Reports.

[43]  Marenao Tanaka,et al.  Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10‐Year Period in Both Male and Female Subjects , 2021, Journal of the American Heart Association.

[44]  Bingong Li,et al.  Relationship between Plasma Trimethylamine N-Oxide Levels and Renal Dysfunction in Patients with Hypertension , 2021, Kidney and Blood Pressure Research.

[45]  A. Hekmatdoost,et al.  The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies , 2021, EXCLI journal.

[46]  H. Degirmenci,et al.  Predictors of left atrial remodeling in newly diagnosed hypertensive patients: a speckle-tracking echocardiographic study , 2021, The International Journal of Cardiovascular Imaging.

[47]  D. Seals,et al.  Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans , 2021, Hypertension.

[48]  Feng Ma,et al.  Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease , 2021, Metabolites.

[49]  B. Zhong,et al.  Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis , 2021, Lipids in Health and Disease.

[50]  Hao-Jie Zhong,et al.  Risk Factors for Intestinal Barrier Impairment in Patients With Essential Hypertension , 2021, Frontiers in Medicine.

[51]  C. Borghi,et al.  Uric Acid and Hypertension: Prognostic Role and Guide for Treatment , 2021, Journal of clinical medicine.

[52]  A. Sîngeap,et al.  Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications , 2021, Canadian journal of gastroenterology & hepatology.

[53]  J. Viikari,et al.  Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) , 2021, Annals of medicine.

[54]  Chongyang Ma,et al.  The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis , 2021, Bioengineered.

[55]  K. Gariani,et al.  Pathophysiology of NASH in endocrine diseases , 2021, Endocrine connections.

[56]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[57]  C. Byrne,et al.  NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. , 2020, Diabetes & metabolism.

[58]  P. Chun Therapeutic effects of histone deacetylase inhibitors on heart disease , 2020, Archives of Pharmacal Research.

[59]  A. Masclee,et al.  Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[60]  A. Anwar,et al.  Correlation Between Body Mass Index and Blood Pressure Levels Among Hypertensive Patients: A Gender-Based Comparison , 2020, Cureus.

[61]  M. Nieuwdorp,et al.  Gut Microbiota in Hypertension and Atherosclerosis: A Review , 2020, Nutrients.

[62]  A. Sherman,et al.  Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. , 2020, American journal of physiology. Endocrinology and metabolism.

[63]  М. И. Туровец,et al.  Влияние неалкогольной жировой болезни печени на показатели артериальной жесткости и риск сердечно-сосудистых осложнений у пациентов с артериальной гипертензией , 2020 .

[64]  A. Cox,et al.  Trimethylamine N-oxide: heart of the microbiota–CVD nexus? , 2020, Nutrition Research Reviews.

[65]  T. Goeser,et al.  NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.

[66]  K. Guan,et al.  Role of Leptin in Cardiovascular Diseases , 2020, Frontiers in Endocrinology.

[67]  L. Schomburg,et al.  Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis , 2020, Nutrients.

[68]  Xuan Li,et al.  Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. , 2020, The Canadian journal of cardiology.

[69]  H. El‐Serag,et al.  Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[70]  F. Wei,et al.  Higher Serum Uric Acid Level Predicts Non-alcoholic Fatty Liver Disease: A 4-Year Prospective Cohort Study , 2020, Frontiers in Endocrinology.

[71]  I. Seong,et al.  A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults , 2020, Korean circulation journal.

[72]  M. Lanaspa,et al.  Uric acid and Hypertension: An Update with Recommendations. , 2020, American journal of hypertension.

[73]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[74]  M. Dai,et al.  Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis , 2020, Mediators of inflammation.

[75]  R. Costa,et al.  Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? , 2020, Clinics and research in hepatology and gastroenterology.

[76]  L. T. ’t Hart,et al.  The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[77]  P. Whelton,et al.  High Blood Pressure and Cardiovascular Disease , 2019, Hypertension.

[78]  Hongliang Li,et al.  Nonalcoholic Fatty Liver Disease , 2019, Hypertension.

[79]  F. Montecucco,et al.  Impact of different ectopic fat depots on cardiovascular and metabolic diseases , 2019, Journal of cellular physiology.

[80]  Lei Liu,et al.  Acetate Affects the Process of Lipid Metabolism in Rabbit Liver, Skeletal Muscle and Adipose Tissue , 2019, Animals : an open access journal from MDPI.

[81]  O. Cummings,et al.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.

[82]  W. Ling,et al.  Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. , 2019, Molecular nutrition & food research.

[83]  C. Richart,et al.  Circulating microbiota-derived metabolites: a “liquid biopsy? , 2019, International Journal of Obesity.

[84]  Huang-Ping Yu,et al.  Associations between neonatal serum bilirubin and childhood hypertension , 2019, PloS one.

[85]  H. Fan,et al.  The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis. , 2019, Advances in nutrition.

[86]  Hyunyoung Jeong,et al.  Characterization of Vitamin A Metabolome in Human Livers With and Without Nonalcoholic Fatty Liver Disease , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[87]  Roy Taylor,et al.  The degree of hepatic steatosis associates with impaired cardiac and autonomic function. , 2019, Journal of hepatology.

[88]  Q. Pan,et al.  Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats , 2019, World journal of gastroenterology.

[89]  E. Paschetta,et al.  Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation , 2019, The American journal of gastroenterology.

[90]  C. Borghi,et al.  Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. , 2019, Journal of hypertension.

[91]  He-dong Lang,et al.  SIRT3 Deficiency Promotes High‐Fat Diet‐Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis , 2018, Molecular nutrition & food research.

[92]  G. Muscogiuri,et al.  Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome , 2018, Nutrients.

[93]  L. Pączek,et al.  Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats. , 2018, American journal of physiology. Heart and circulatory physiology.

[94]  L. Navar,et al.  Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure , 2018, Current Hypertension Reports.

[95]  D. Schuppan,et al.  Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany , 2018, Alimentary pharmacology & therapeutics.

[96]  Houkai Li,et al.  The Role of Gut Microbiota in Atherosclerosis and Hypertension , 2018, Front. Pharmacol..

[97]  M. He,et al.  Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. , 2018, Journal of the American Society of Hypertension : JASH.

[98]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[99]  R. Kurosawa,et al.  Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target , 2018, Circulation.

[100]  Zhiye Wu,et al.  Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis , 2018, Laboratory Investigation.

[101]  D. Tousoulis,et al.  Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? , 2018, European journal of gastroenterology & hepatology.

[102]  O. Giouleme,et al.  Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? , 2018, Current vascular pharmacology.

[103]  C. Pepine,et al.  Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. , 2018, Clinical science.

[104]  A. Bulmer,et al.  Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. , 2018, American journal of physiology. Heart and circulatory physiology.

[105]  Y. Ilan Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment , 2018, Annals of gastroenterology.

[106]  P. Strazzullo,et al.  Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links , 2018, High Blood Pressure & Cardiovascular Prevention.

[107]  A. Lonardo,et al.  Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? , 2018, Journal of hepatology.

[108]  K. Faber,et al.  Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD) , 2017, Nutrients.

[109]  Tianxin Yang,et al.  Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin–angiotensin system , 2017, Journal of hypertension.

[110]  S. O’Brien,et al.  Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma , 2017, PloS one.

[111]  Arijit Ghosh,et al.  Role of free fatty acids in endothelial dysfunction , 2017, Journal of Biomedical Science.

[112]  M. Watt,et al.  Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance , 2017, Nature Reviews Endocrinology.

[113]  A. Peters,et al.  Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease , 2017, Journal of hypertension.

[114]  M. Siedlinski,et al.  Novel Immune Mechanisms in Hypertension and Cardiovascular Risk , 2017, Current Cardiovascular Risk Reports.

[115]  B. Egan Physical Activity and Hypertension: Knowing Is Not Enough; We Must Apply. Willing Is Not Enough; We Must Do-von Goethe. , 2017, Hypertension.

[116]  B. Balkau,et al.  Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies , 2017, Journal of hypertension.

[117]  D. Levy,et al.  Bi-directional analysis between fatty liver and cardiovascular disease risk factors. , 2017, Journal of hepatology.

[118]  C. Pepine,et al.  Hypertension-Linked Pathophysiological Alterations in the Gut , 2017, Circulation research.

[119]  Zhiheng Chen,et al.  Hypertension and non‐alcoholic fatty liver disease proven by transient elastography , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[120]  E. Schleicher,et al.  The impact of insulin resistance on the kidney and vasculature , 2016, Nature Reviews Nephrology.

[121]  H. Ho,et al.  Hepatic manifestations of women with polycystic ovary syndrome. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[122]  A. Fasano,et al.  Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases , 2016, Tissue barriers.

[123]  S. Flavahan,et al.  Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. , 2016, Physiological genomics.

[124]  Yingying Ding,et al.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.

[125]  H. Itoh,et al.  The role of short-chain fatty acid on blood pressure regulation , 2016, Current opinion in nephrology and hypertension.

[126]  K. Sung,et al.  Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study , 2016, Medicine.

[127]  A. Johnson,et al.  Leptin Mediates High-Fat Diet Sensitization of Angiotensin II–Elicited Hypertension by Upregulating the Brain Renin–Angiotensin System and Inflammation , 2016, Hypertension.

[128]  G. Salles,et al.  NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? , 2016, International journal of molecular sciences.

[129]  L. Cugusi,et al.  Arterial hypertension in the female world: pathophysiology and therapy. , 2016, Journal of cardiovascular medicine.

[130]  N. Zakopoulos,et al.  Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center , 2016, Clinical and experimental gastroenterology.

[131]  Y. Kim,et al.  Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease , 2015, Medicine.

[132]  Eung Ju Kim,et al.  A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study , 2015, PloS one.

[133]  M. Blaha,et al.  Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk , 2015, Journal of hypertension.

[134]  C. Pepine,et al.  Gut Dysbiosis Is Linked to Hypertension , 2015, Hypertension.

[135]  Xiaofang Chen,et al.  Relationship between Serum Bilirubin and Left Ventricular Hypertrophy in Patients with Essential Hypertension , 2015, PloS one.

[136]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[137]  R. Chowdhury,et al.  Circulating Total Bilirubin and Risk of Incident Cardiovascular Disease in the General Population , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[138]  M. Dave,et al.  Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability , 2015, Cellular and molecular gastroenterology and hepatology.

[139]  R. Feng,et al.  Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. , 2014, World journal of gastroenterology.

[140]  C. Roberts,et al.  Sex-Specific Differences in Lipid and Glucose Metabolism , 2014, Front. Endocrinol..

[141]  Y. Cho,et al.  Clinical association between non‐alcoholic fatty liver disease and the development of hypertension , 2014, Journal of gastroenterology and hepatology.

[142]  R. Brandes Endothelial dysfunction and hypertension. , 2014, Hypertension.

[143]  S. Wild,et al.  Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.

[144]  H. J. Yoo,et al.  Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. , 2013, Biochemical pharmacology.

[145]  H. J. Yoo,et al.  The effects of caloric restriction on Fetuin‐A and cardiovascular risk factors in rats and humans: a randomized controlled trial , 2013, Clinical endocrinology.

[146]  M. Ermani,et al.  Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[147]  A. Arnold,et al.  Metabolic impact of sex chromosomes , 2013, Adipocyte.

[148]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[149]  Y. Kesäniemi,et al.  High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults , 2012, Journal of hypertension.

[150]  Peter Tontonoz,et al.  The Number of X Chromosomes Causes Sex Differences in Adiposity in Mice , 2012, PLoS genetics.

[151]  K. Sandberg,et al.  Sex differences in primary hypertension , 2012, Biology of Sex Differences.

[152]  D. Stec,et al.  Bilirubin, Renal Hemodynamics, and Blood Pressure , 2012, Front. Pharmacol..

[153]  H. J. Yoo,et al.  Effects of a three‐month combined exercise programme on fibroblast growth factor 21 and fetuin‐A levels and arterial stiffness in obese women , 2011, Clinical endocrinology.

[154]  B. Graubard,et al.  Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database , 2011, Hepatology.

[155]  R. Prough,et al.  Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. , 2011, Chemico-biological interactions.

[156]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[157]  D. Stec,et al.  Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[158]  A. Hida,et al.  Fatty liver incidence and predictive variables , 2010, Hypertension Research.

[159]  Yutaka Takeda,et al.  Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension , 2010, BMC pulmonary medicine.

[160]  L. Terracciano,et al.  Predicting Fibrosis Worsening in Obese Patients With NASH Through Parenchymal Fibronectin, HOMA-IR, and Hypertension , 2010, The American Journal of Gastroenterology.

[161]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[162]  Paul L. Huang A comprehensive definition for metabolic syndrome , 2009, Disease Models & Mechanisms.

[163]  Y. Nie,et al.  Prevalence of fatty liver disease and its risk factors in the population of South China. , 2007, World journal of gastroenterology.

[164]  S. Bloc,et al.  Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[165]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[166]  S. Oparil,et al.  Gender and Blood Pressure , 2005, Journal of clinical hypertension.

[167]  V. Somers,et al.  Gender-Selective Interaction Between Aging, Blood Pressure, and Sympathetic Nerve Activity , 2005, Hypertension.

[168]  Andries J. Smit,et al.  Autonomic Function in Hypertensive and Normotensive Subjects: The Importance of Gender , 2001, Hypertension.

[169]  J F Reckelhoff,et al.  Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.

[170]  Alessandro Sebastian Podda,et al.  Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. , 2000, The American journal of cardiology.

[171]  Y. Sugiyama,et al.  Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[172]  H. Vu,et al.  Association between nonalcoholic fatty liver disease and carotid intima-media thickness. , 2023, Clinica Terapeutica.

[173]  T. Luedde,et al.  Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD) , 2023 .

[174]  Ezona E Ntlahla,et al.  Gut permeability is associated with hypertension and measures of obesity but not with Endothelial Dysfunction in South African youth , 2021, African Health Sciences.

[175]  R. Loomba,et al.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[176]  Sean M. Kearney,et al.  Mining the microbiota for microbial and metabolite-based immunotherapies , 2019, Nature Reviews Immunology.

[177]  R. Touyz,et al.  Oxidative Stress, Inflammation, and Vascular Aging in Hypertension , 2017, Hypertension.

[178]  S. Upala,et al.  Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2017, Annals of hepatology.

[179]  Shohei Matsuzaki,et al.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background , 2003, Journal of Gastroenterology.

[180]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .